Physician profile
Neil Talon
NPI 1851401368
$1,811.79
in general payments reported to CMS, 2019-2025
12 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.01 · 2020: $211 · 2021: $46.57 · 2022: $12.90 · 2024: $357 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $481.57 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $233.10 | 2025 | Austedo Xr |
| Allergan, INC. | $146.57 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $140.08 | 2025 | Qelbree |
| Abbvie INC. | $128.46 | 2021-2025 | |
| Noven Pharmaceuticals, INC. | $124.74 | 2024 | Xelstrym |
| Noven Therapeutics, LLC | $124.74 | 2025 | Xelstrym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.74 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $121.35 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $111.74 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $45.89 | 2019-2022 | |
| Lundbeck LLC | $28.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Talon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.